Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06892145 | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE | PHASE1 | RECRUITING | 12 | — | — | Jun 12, 2025 | Feb 16, 2028 | Dec 22, 2025 | 2 | China |
Dose-limiting toxicity after CD19 CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| MC-1-50 | EXPERIMENTAL | Patients will be be treated with CD19 CAR- T cells |
| Name | Type | Description |
|---|---|---|
| MC-1-50 | BIOLOGICAL | A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy |
Inclusion Criteria: 1. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study; 2. Age ≥ 18 years old , gender not limited; 3. Patient...